News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Cardiff Lexington CEO Alex Cunningham Discusses Healthcare Growth Strategy

Cardiff Lexington Corporation

Cardiff Lexington CEO Alex Cunningham joined Steve Darling from Proactive to discuss the company's transformation into an acquisition-oriented healthcare firm with a focus on orthopedic surgery centers. Cardiff Lexington's revenue primarily stems from bodily injury and general liability insurance coverages, providing insulation from pricing downsides associated with Medicare and Medicaid. Cunningham emphasized the unique accounts receivable structure of the company, along with its focus on uninsured coverages, which contribute to maintaining high collectability rates. He also highlighted the increasing demand for orthopedic services driven by an aging population, positioning Cardiff Lexington for growth in this market. The company's recent financial performance showed significant increases in revenue, net earnings, and assets, reflecting its strategic focus and operational efficiency. Looking ahead to 2024, Cardiff Lexington plans to continue its expansion through acquisitions, market expansion initiatives, and strategic partnerships. Furthermore, Cunningham mentioned the company's plans to release its 10k in early March and pursue an uplift to a major exchange in 2024, with a clear focus on enhancing shareholder value and achieving strategic growth objectives. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 26, 2024 10:32 AM Eastern Standard Time

Video
Article thumbnail News Release

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

IQ-AI Ltd

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblastoma patients. Connelly explained that glioblastoma, the most common malignant brain tumour, significantly impacts brain function, highlighting the importance of clinical trials to improve patient quality of life. The trial, opened nearly two years ago, investigates gallium maltolate, an oral medication showing promise in preclinical studies and animal models for efficacy against tumour cells. This phase focuses on drug tolerance, with patients reporting ease of use compared to traditional treatments and the ability to maintain normal daily activities. An expanded access programme (EAP), also known as compassionate use, has been launched by IA-AI subsidiary Imaging Biometric to allow wider access to gallium maltolate across the country, benefiting patients unable to travel to the Medical College of Wisconsin. The EAP, approved by the FDA, aims to collect additional safety and toxicity data, contributing to the trial's findings and supporting the progression towards a phase two clinical trial. The next milestone, by the end of 2024, involves concluding the phase one trial, determining the maximum tolerated dose, and preparing for the phase two trial slated for 2025, focusing on safety and beginning to evaluate efficacy. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

February 26, 2024 09:51 AM Eastern Standard Time

Video
Article thumbnail News Release

Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants

Elutia Inc.

Elutia CEO Randy Mills joined Steve Darling from Proactive to discuss the company's groundbreaking product, CanGarooRM, a drug-eluting biologic designed to safeguard implanted medical devices such as pacemakers. Founded by Mills and Kevin Rakin, both esteemed veterans in the biotech industry, Elutia aims to revolutionize healthcare by combining regenerative medicine with localized drug delivery. Mills shed light on CanGarooRM's unique formulation, which includes antibiotics to prevent infections and device migration, ultimately enhancing patient safety. With the FDA accepting their filing in December, Elutia is optimistic about receiving favorable results in the second quarter of this year. If approved, CanGarooRM has the potential to capture a significant share of the market, estimated to exceed $500 million. Mills further elaborated that Elutia has completed product development and is poised to commence commercial production by the late second quarter. A soft launch is planned for the third quarter, followed by full-scale deployment by the fourth quarter of this year. This strategic timeline positions Elutia for substantial growth pending regulatory approval, with CanGarooRM poised to address critical needs in the healthcare industry and improve patient outcomes. In summary, the interview underscored Elutia's promising trajectory and the transformative potential of CanGarooRM in enhancing medical device safety. With a strong foundation in regenerative medicine and localized drug delivery, Elutia is poised to make a significant impact in healthcare innovation, driving positive change and improving patient care globally. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:37 AM Eastern Standard Time

Video
Article thumbnail News Release

Cloud DX secures key partnership with Sanrai International for worldwide distribution

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to announce a new Partnership Agreement with New York-based Sanrai International. Sanrai International, a leading medical device distribution company with a global presence, will now market and resell the Cloud DX Connected Health platform across more than 65 countries. Kaul highlighted the significance of this partnership, emphasizing Sanrai's extensive customer and sub-distributor network, which spans Latin America, Africa, the Middle East, Asia, and beyond. The focus of this collaboration will be on addressing chronic disease management and post-surgical recovery, leveraging Cloud DX's innovative Connected Health products and services. With the partnership in place, both Cloud DX and Sanrai aim to equalize access to innovative medical devices, particularly in the areas of chronic illness and post-surgical recovery. Kaul also mentioned that Cloud DX has already announced over $2.5 million CAD in new business in 2024, reflecting the company's continued growth and market expansion efforts. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:06 AM Eastern Standard Time

Video
Article thumbnail News Release

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Andrew Reynolds as Senior Director of Equity Trading.

Roberts & Ryan, Inc.

Andrew Reynolds joins Roberts & Ryan as Senior Director of Equity Trading and has more than 30 years of experience in equity trading, capital markets, portfolio management, options & derivatives, sales & business development, investor relations, and corporate compliance. Prior to joining Roberts & Ryan, Mr. Reynolds was Head of Equity Trading and a Registered Principal at Tullett Prebon and KCCI Ltd. Before that, he was Head Trader and Floor Broker at Tradition North America and R.J. Murphy & Associates. Prior to that, he was Head Trader at Preferred Technology. Mr. Reynolds began his career as an Options Clerk at Pershing, LLC. “Andrew brings extensive experience in equity trading and represents Roberts & Ryan’s commitment to providing best in class service and execution,” said James McDevitt, Roberts & Ryan’s Senior Director of Equity Sales and Trading, Capital Markets. “He will be a tremendous advocate for our social mission of supporting veterans and their families. I’m very excited to have him join our team.” Mr. Reynolds is a member of the Securities Traders Association (STA), the Securities Traders Association of New York (STANY), Philadelphia Traders (ITAP), and the National Investor Relations Institute (NIRI). He holds SIE and FINRA Series 7, 24, 25, 55, 57 & 63 licenses. Mr. Reynolds served as a Technical Warfare Specialist, Team Leader, and Group Leader in the 25 th Infantry Division of the United States Army and is a graduate of Archbishop Ryan in Philadelphia. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 19, 2024 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

RapidClaims uses AI to help US healthcare providers address $250b in denied claims

RapidClaims

Healthcare organizations are turning to automation with “revenue cycle management” to protect operating margins and the increasing claim denials from the payors. Every year, close to $265B in claims made by US healthcare organizations are denied because of the way claims are coded on payor documentation and delayed submissions are two chief reasons for the denials. Coding errors account for over 40% of claim denials, while untimely submissions contribute to 35% of denials; eligibility and prior authorization being some of the other aspects playing a significant role. Addressing this pain point, RapidClaims has today emerged from stealth with a $3.1 million funding round to tackle the claims denial problem head-on with its medical coding automation module. The seed round was led by Together Fund, a $250 million global SaaS fund, with participation from Better Capital, Neon Fund, Peercheque, DeVC with angels and advisors coming from prominent US healthcare organizations including Oscar Benavidez (Executive Director, Mass General), Ankit Jain (Founder & CEO of Infinitus), and Sachin Jain (President & CEO of Scan Health) among others. RapidClaims is led by Dushyant Mishra (CEO), Jot Sarup Sahni (CPTO), and Abhinay Vyas (CDO), each bringing a nuanced understanding of healthcare, data science, and scaling tech products. The idea for RapidClaims originated in 2018 during Dushyant Mishra’s tenure at Abbott Healthcare when he observed the challenges faced by hospitals while interacting with multiple hospital owners and physicians. Since then, he has closely monitored the space, which gained significant momentum in 2022 as two key trends emerged: an increase in claim denial rates across the US and the effective demonstration of large language models (LLMs) as a solution to these challenges. RapidClaims recognizes the diverse challenges inherent in revenue cycle management. With a strategic focus on tackling medical coding initially, the company aims to simplify the rising complexity of coding processes and leverage the potential for AI to drive efficiencies over time. In recent years, coding complexity has surged significantly with diagnosis codes like ICD codes rising from 19,000 (ICD 9) to nearly 120,000 (ICD 11). Adherence to guidelines is becoming increasingly challenging due to rapid changes encompassing NCCI edits, NCD/LCD guidelines, Medicare policies, payor rule sets, among others. RapidClaims has achieved success with six pilots within two months of its beta product launch in June 2023 and is poised to enhance product robustness even further with an additional five pilots already in the pipeline. Dushyant Mishra, Founder & CEO of RapidClaims commented: "We are just beginning to witness tangible benefits in terms of cost savings, speed, and revenue enhancement through AI utilization. While automation is pivotal, we recognize the indispensable role of coders with their nuanced understanding of intricate rules and edge cases. This is the driving force behind our significant investment in the RapidAssist product, which has the transformative potential to elevate medical coding operations for coder-managing teams." AI holds immense potential for introducing exceptional efficiencies into this domain. Beyond identifying the right code, AI's current state allows for precise context interpretation, adding a layer of sophistication to the coding process. RapidClaims has unveiled three multi-specialty products aimed at alleviating coding administrative overload: RapidCode: Fully autonomous medical coding, streamlining the process with end-to-end automation. RapidAssist: A tailored tool for medical coders designed to improve productivity by auditing charts and identifying documentation gaps, which includes a query builder and rule-set engine. RapidRisk: Advanced AI for risk-adjusted coding that calculates HCC and RAF scores while pinpointing opportunities for documentation improvement based on a comprehensive rule set developed in collaboration with prominent CDI leaders. More healthcare organizations are recognizing the need for revenue cycle automation to overcome workforce challenges, handle increasing claim volumes, mitigate revenue losses, and navigate the complexities of healthcare administration. This urgency is further fueled by the rise in claim denials from payors, which puts significant pressure on healthcare providers and exacerbates the already high administrative costs. A recent study conducted by Bain & Company and KLAS reveals that 80% of U.S. healthcare providers are increasing their investment in IT and software, with a specific focus on prioritizing AI technologies. Revenue cycle transformation and automation are the top areas of focus for healthcare executives. Manav Garg, Co-founder of Together Fund added: "We are thrilled about the transformative potential of AI in optimizing administrative processes within the revenue cycle. We are confident that the RapidClaims team embodies the perfect blend of expertise, showcasing an in-depth understanding of the complexities within the U.S. healthcare system coupled with exceptional proficiency in artificial intelligence." About RapidClaims RapidClaims is automating medical coding to help health organizations reduce claim denials from payors. About Together Fund Together Fund is an enterprise software-focused, operator-led fund started by Girish Mathrubootham (Founder, Freshworks ), Manav Garg (Founder, Eka ) and Shubham Gupta (ex Matrix Partners). Together invests in Seed and Series A opportunities across AI, Devtools, Cloud Infra, Security, Horizontal & Vertical SaaS applications. With a “for-founders, by-founders” DNA, Together is joined by 150+ global founders & operators in this endeavor to help build global products. Contact Details RapidClaims Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.rapidclaims.ai/

February 16, 2024 06:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Creo Medical Group expands reach of Speedboat UltraSlim; announces tie-up with Abu Dhabi university

Creo Medical Group PLC

Creo Medical Group CEO Craig Gulliford joined Proactive's Stephen Gunnion following the deployment of the Speedboat UltraSlim device in the Asia Pacific region, marking a significant milestone for the company. The Speedboat UltraSlim, a culmination of years of development, miniaturizes laparoscopic advanced energy capabilities into a compact device enhancing endoscopic surgery. This innovation enables precise surgical procedures with minimal invasiveness, targeting precancerous and cancerous lesions in the gastrointestinal tract. Gulliford highlighted the device's successful clinical applications in various regions, including the US, South America, Europe, and recently at the Prince of Wales Hospital in Hong Kong, focusing on stomach and colon lesions. The technology aims to reduce the need for conventional surgery, offering a safer alternative with lower complication rates. Additionally, Creo announced a strategic collaboration with Khalifa University of Science and Technology in Abu Dhabi to develop intellectual property and expand its technological reach into the Middle East. This partnership aims to foster innovation and enhance medical outcomes, reinforcing Creo Medical's commitment to advancing medical technology and improving patient care globally. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 12, 2024 10:00 AM Eastern Standard Time

Video
Article thumbnail News Release

Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to highlight certain significant favorable market developments creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies. This comes after the U.S. FDA granted, for the first time ever, a clearance to the Vivos CARE appliances to treat moderate and severe OSA in adults, (18 years of age and older) with positive airway pressure and/or myofunctional therapy, as needed. Huntsman highlighted several other factors contributing to the positive market conditions for Vivos. The recent discontinuation of many devices by Philips Respironics is expected to disrupt the supply chain, potentially affecting patient care. Additionally, the recalls of continuous positive airway pressure (CPAP) devices have left millions of OSA sufferers searching for alternative treatments. United Healthcare's recognition of oral appliance therapy as a prerequisite for surgical treatment in adult patients with moderate to severe OSA is another important development. These factors are collectively creating a significant opportunity for Vivos to expand its user base and offer effective treatment options to those in need. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

February 12, 2024 09:24 AM Eastern Standard Time

Video
Article thumbnail News Release

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Andrew Reynolds as its newest Managing Director.

Roberts & Ryan, Inc.

Andrew Reynolds joins Roberts & Ryan as Managing Director and has more than 30 years of experience in equity trading, capital markets, portfolio management, options & derivatives, sales & business development, investor relations, and corporate compliance. Prior to joining Roberts & Ryan, Mr. Reynolds was Head of Equity Trading and a Registered Principal at Tullett Prebon and KCCI Ltd. Before that, he was Head Trader and Floor Broker at Tradition North America and R.J. Murphy & Associates. Prior to that, he was Head Trader at Preferred Technology. Mr. Reynolds began his career as an Options Clerk at Pershing, LLC. “Andrew brings extensive experience in equity trading and represents Roberts & Ryan’s commitment to providing best in class service and execution,” said James McDevitt, Roberts & Ryan’s Senior Director of Equity Sales and Trading, Capital Markets. “He will be a tremendous advocate for our social mission of supporting veterans and their families. I’m very excited to have him join our team.” Mr. Reynolds is a member of the Securities Traders Association (STA), the Securities Traders Association of New York (STANY), Philadelphia Traders (ITAP), and the National Investor Relations Institute (NIRI). He holds SIE and FINRA Series 7, 24, 25, 55, 57 & 63 licenses. Mr. Reynolds served as a Technical Warfare Specialist, Team Leader, and Group Leader in the 25 th Infantry Division of the United States Army and is a graduate of Archbishop Ryan in Philadelphia. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 12, 2024 09:00 AM Eastern Standard Time

Image
1 ... 678910 ... 95